1. Home
  2. GTEC vs LNAI Comparison

GTEC vs LNAI Comparison

Compare GTEC & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenland Technologies Holding Corporation

GTEC

Greenland Technologies Holding Corporation

HOLD

Current Price

$0.53

Market Cap

13.4M

Sector

Industrials

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

BUY

Current Price

$0.25

Market Cap

11.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
GTEC
LNAI
Founded
2006
N/A
Country
United States
United States
Employees
340
29
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
11.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GTEC
LNAI
Price
$0.53
$0.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
101.6K
3.3M
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.62
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.15
52 Week High
$2.26
$1.66

Technical Indicators

Market Signals
Indicator
GTEC
LNAI
Relative Strength Index (RSI) 34.30 37.06
Support Level $0.47 $0.15
Resistance Level $0.80 $0.41
Average True Range (ATR) 0.05 0.03
MACD -0.01 -0.00
Stochastic Oscillator 34.79 1.72

Price Performance

Historical Comparison
GTEC
LNAI

About GTEC Greenland Technologies Holding Corporation

Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: